Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

5 Spanish Centers Join A Study For A New Leukemia And Lymphoma Treatment Technique
The Gamida Cell-Teva Joint Venture have today that five prestigious cord blood transplantation centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study.
generic viagra online
Spiration Announces The Participation Of Several New Sites In U.S. Pivotal Trial Of Minimally Invasive Treatment For Severe Emphysema
Spiration, Inc., a developer of novel medical devices designed to benefit patients with acute and chronic conditions of the lung, announced today that several new clinical sites are now actively recruiting patients for participation in a pivotal trial of the company"s minimally invasive treatment for severe emphysema. Drugshop to buy zoloft online and other pills.
News of the day
Infection Prevention Text Updated, Improved - The APIC Text Of Infection Control And Epidemiology
More than 300 infection prevention experts have completed a text that serves as one of the most valuable tools for infection preventionists throughout the world, the APIC Text of Infection Control and Epidemiology. The 1,700-page document, now in its 3rd edition, has been completely revised and is now available, offering a concise information re containing more than 120 expanded and enhanced chapters.
Endocrinology

Researchers Develop Questions To Determine Risk Of HIV/AIDS Drug Resistance

Researchers from the Makerere University hospital in Uganda, the U.S. and Belgium have developed a formula, based on a set of questions, for determining HIV-positive people"s risk of treatment failure and drug resistance, according to a study recently published in the Journal of the International AIDS Society, the New York Times reports. According to the Times, most HIV-positive people in Africa rarely have access to viral load tests to determine if they are developing resistance to first-line antiretroviral drugs because the testing is expensive and complicated.The researchers questioned 496 HIV-positive people about: *How often they had taken their drugs in the past three days, the previous four weeks and since they began treatment; *If they had ever missed two days of drugs; *If they had ever paid for treatment; *Whether women had ever taken nevirapine to prevent mother-to-child transmission; and *If the patients had experienced weight loss or rashes. The researchers also took blood samples to determine the participants" CD4+ T cell counts. They found that having ever missed treatment for two days or a 30% decrease in CD4+ count predicted treatment failure. The researchers said that viral load testing, when available, be given to these patients first. In addition, the Times reports that the new method appears to work better than World Health Organization guidelines, which are based on clinical signs of HIV progression and CD4+ counts (McNeil, New York Times, 5/18). The study is available online. Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009